tradingview.comOCT 301 min read$MBRX

Moleculin Biotech Completes MIRACLE Part A Dosing; Data Readout on Track for Q1 2027

Moleculin Biotech completed dosing in Part A of its MIRACLE trial for AnnAraC, a treatment for relapsed or refractory AML, with 90 patients. Data analysis is expected in Q1 2027 to determine the dose for Part B. The trial includes patients who failed 7+3 and venetoclax-based regimens, according to the company.

Original reporting

tradingview.com

Published Oct 30, 2026, 12:53 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 30, 2026, 12:57 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Moleculin Biotech Completes MIRACLE Part A Dosing; Data Readout on Track for Q1 2027 — source image — Source · tradingview.com

Decision brief

The 30-second read

$MBRXBullishMed

Why it matters

The dosing milestone moves the trial into data collection phase, setting up Q1 2027 readout.

Market read

Trial progress could affect biotech sector sentiment and related stocks.

What to watch

Potential delays in data readout or trial setbacks could dampen impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Moleculin Biotech is developing AnnAraC for AML; trial dosing just completed.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MBRXBullishMedium confidence

Context

Completed dosing in Part A of its pivotal MIRACLE trial for relapsed AML.

Expected impact

potential upside as investors price in upcoming efficacy data

Evidence & confidence

Trial milestone is positive but no efficacy data yet, so impact is speculative

Market effects

Sector

May lift sentiment in oncology biotech space.

Regional

Primarily US biotech investors.

Global

Limited to global biotech investors tracking AML therapies.

Counterpoint

What could challenge this read

Without efficacy data, the dosing news may be overhyped.

Key entities

company
Moleculin Biotech
Biotech firm developing AnnAraC for relapsed/refractory AML.

Read at source ← All news

NOV 4

$MBRXHighAI 9/10

Moleculin Biotech, Inc. (MBRX) Reports 43% and 36% Remission Rates in Interim Trial

Moleculin Biotech reported interim Phase 2/3 trial results showing 43% and 36% remission rates in two Annamycin arms, compared to 12% with placebo. The Data Monitoring Committee recommended continuing the study. The next update is expected in early 2027.

tradingview.com2 min

NOV 4

$MBRXMedAI 8/10

Interim leukemia data show complete remission rates of 43% and 36% in two groups, versus 12% on placebo.

Moleculin Biotech (MBRX) reported interim Phase 2/3 trial data for Annamycin in relapsed/refractory AML, showing 43% and 36% remission rates vs. 12% on placebo. The study will continue, with results to be presented at the 2026 ASH Annual Meeting. If successful, it could support a New Drug Application submission.

stocktitan.net4 min

OCT 31

Low

Moleculin Biotech Completes Dosing in Phase 2/3 MIRACLE Trial for AnnAraC

Moleculin Biotech completed dosing in Part A of its Phase 2/3 MIRACLE trial for AnnAraC in R/R AML patients. The company expects comprehensive data in Q1 2027, which will confirm or challenge earlier interim results showing higher remission rates. Success could support FDA filings.

clinicaltrialvanguard.com2 min

OCT 30

$MBRXLow

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute mye

SEC EDGAR 8-K2 min

OCT 30

$MBRXLow

Dosing is complete for 90 people in a leukemia trial.

Moleculin Biotech (MBRX) completed dosing for 90 patients in Part A of its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). The company expects to report comprehensive data in Q1 2027, which will support dose selection for Part B. Annamycin is designed to avoid multidrug resistance and lacks cardiotoxicity common with other treatments.

stocktitan.net2 min

OCT 20

$MYGNHighAI 8/10

Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%

Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.

rttnews.com2 min